Sarcoidosis
ICD-10 D86 · ICD-11 4B20

Treatment of Sarcoidosis in Neurosarcoidosis with Mild to Moderately Disabling Disease

When sarcoidosis involves the nervous system with mild to moderate functional impact, the pattern of neurological involvement shapes the treatment strategy. This protocol addresses that specific clinical setting.

Clinical Scenario — Neurosarcoidosis

This protocol applies to patients with neurosarcoidosis presenting with mild to moderately disabling features, including:

Cranial neuropathy — nerve II Cranial neuropathy — nerve VIII Meningeal mass lesions Hydrocephalus CNS parenchymal disease Peripheral neuropathies Generalized myopathies
Treatment Approach

Management in this setting may involve anti-TNF therapy or intravenous corticosteroids. The full selection criteria, agent choice, and complete regimen details are available in the structured protocol.

Treatment Goal
✓

Clinical response within 2–3 months.

Instant Access to Structured Evidence-Based Regimens

References

  1. It is suggested that patients with mild to moderately disabling disease (cranial nerves II and VIII, meningeal mass lesions, hydrocephalus, CNS parenchymal disease, neuropathies and generalized myopathies) be treated with 20-30 mg prednisone daily for at least one month.
  2. Infliximab can also be used for chronic treatment or to "bridge" a patient until an immunosuppressive drug's benefit becomes evident, typically in 2-3 months.
  3. Infusions of infliximab can be administered every 2-8 weeks, or at longer intervals, as clinically indicated.
View source ↗